EUVIMEDOpdag EUVIMED
Netzwerk-MetaanalyseSystematische Übersicht

Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA

Binayak Sinha, Samit Ghosal iD

Obesity · 2025-11 · 33 (11) · 2046-2054

DOI: 10.1002/oby.24360 ↗

At a glance

Netzwerk-Metaanalyse in Obesity, published online on 2025-07-20. Written by Binayak Sinha and 1 co-authors. Institution: Department of Endocrinology, Manipal Hospital, Kolkata, India. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Overweight, Weight Loss. Cited 25 times so far (Crossref); 27 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

To compare the efficacy and safety of GLP‐1 receptor agonists (GLP‐1RAs), dual agonists (GLP‐1RAs/GIP or GCGR), and retatrutide (GLP‐1/GIP/glucagon) for weight loss in adults with overweight or obesity.

Methods

We conducted a systematic review and Bayesian network meta‐analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m 2 ), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo. Outcomes included mean weight loss, achievement of ≥ 5%, ≥ 10%, and ≥ 15% weight loss, waist circumference (WC), BMI, and adverse events (AEs) at ≥ 36 weeks. Subgroup and meta‐regression analyses evaluated the impact of diabetes status, sex, age, and BMI.

Results

Retatrutide and dual agonists achieved equivalent mean weight loss (−11.0 kg), surpassing GLP‐1RAs (−9.0 kg), with retatrutide excelling at achieving ≥ 15% weight loss (OR 54.6). Dual agonists and GLP‐1RAs followed (OR 16.4 and 9.0, respectively). Retatrutide had the highest AE risk. Meta‐regression showed type 2 diabetes mellitus (T2DM) reduced weight loss by 4.338 kg for GLP‐1RAs and 5.016 kg for dual agonists, with enhanced outcomes in female‐dominant or high‐BMI cohorts.

Conclusions

Retatrutide offers superior weight loss efficacy but with a higher AE risk. Dual agonists provide a favorable efficacy–safety balance. Personalized treatment selection based on patient characteristics is recommended. image

Subjects

MeSH terms (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsObesityOverweightWeight LossAdultFemaleHumansMaleBayes TheoremBody Mass IndexDiabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsLiraglutideRandomized Controlled Trials as TopicTirzepatideTreatment OutcomeFatty AcidsPeptidesGlucagon-Like Peptide 1Semaglutide

Author keywords

GLP‐1 receptor agonistsadverse eventsdual agonistsnetwork meta‐analysisobesityretatrutideweight loss

Substances

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsLiraglutideTirzepatideFatty AcidsPeptidesGlucagon-Like Peptide 1Semaglutideretatrutide

Authors and institutions

  • Department of Endocrinology, Manipal Hospital, Kolkata, India.
  • Department of Internal Medicine, Nightingale Hospital, Kolkata, India.

ORCID profiles: Samit Ghosal

Cite

APA

Sinha, B., & Ghosal, S. (2025). Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. Obesity, 33(11), 2046-2054. https://doi.org/10.1002/oby.24360

Vancouver

Sinha B, Ghosal S. Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. Obesity. 2025;33(11):2046-2054. doi:10.1002/oby.24360

BibTeX
@article{Sinha2025,
  author = {Sinha, Binayak and Ghosal, Samit},
  title = {Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA},
  journal = {Obesity},
  year = {2025},
  volume = {33},
  number = {11},
  pages = {2046--2054},
  doi = {10.1002/oby.24360}
}
Start for free →